Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
LAVA Therapeutics Analyst Ratings and Price Targets | NASDAQ:LVTX | Benzinga
LAVA Therapeutics NV has a consensus price target of $9.3 based on the ratings of 5 analysts. The high is $28 issued by SVB Leerink on September 27, 2022. The low is $1.5 issued by HC Wainwright & Co. on February 27, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Leerink Partners on February 27, 2025, December 20, 2024, and December 12, 2024, respectively. With an average price target of $1.83 between HC Wainwright & Co., HC Wainwright & Co., and Leerink Partners, there's an implied 45.50% upside for LAVA Therapeutics NV from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Leerink Partners
JMP Securities
HC Wainwright & Co.
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for LAVA Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/27/2025 | Buy Now | 19.05% | HC Wainwright & Co. | Arthur He37% | $2 → $1.5 | Downgrade | Buy → Neutral | Get Alert |
| 12/20/2024 | Buy Now | 58.73% | HC Wainwright & Co. | Arthur He37% | $6 → $2 | Maintains | Buy | Get Alert |
| 12/12/2024 | Buy Now | 58.73% | Leerink Partners | Daina Graybosch42% | $11 → $2 | Downgrade | Outperform → Market Perform | Get Alert |
| 12/11/2024 | Buy Now | 376.19% | JMP Securities | Reni Benjamin45% | $6 → $6 | Downgrade | Market Outperform → Market Perform | Get Alert |
| 08/21/2024 | Buy Now | 376.19% | JMP Securities | Reni Benjamin45% | $6 → $6 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/28/2024 | Buy Now | 376.19% | HC Wainwright & Co. | Arthur He37% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2024 | Buy Now | 376.19% | HC Wainwright & Co. | Arthur He37% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 11/17/2023 | Buy Now | 376.19% | HC Wainwright & Co. | Arthur He37% | → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/23/2023 | Buy Now | 376.19% | JMP Securities | Reni Benjamin45% | → $6 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/23/2023 | Buy Now | 376.19% | HC Wainwright & Co. | Arthur He37% | $9 → $6 | Maintains | Buy | Get Alert |
| 06/15/2023 | Buy Now | 376.19% | JMP Securities | Reni Benjamin45% | → $6 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/12/2023 | Buy Now | 614.29% | HC Wainwright & Co. | Arthur He37% | → $9 | Reiterates | Buy → Buy | Get Alert |
| 06/09/2023 | Buy Now | 376.19% | JMP Securities | Reni Benjamin45% | → $6 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/13/2023 | Buy Now | 614.29% | HC Wainwright & Co. | Arthur He37% | → $9 | Reiterates | → Buy | Get Alert |
| 02/17/2023 | Buy Now | 614.29% | HC Wainwright & Co. | Swayampakula Ramakanth50% | → $9 | Reiterates | → Buy | Get Alert |
| 10/25/2022 | Buy Now | 614.29% | HC Wainwright & Co. | Arthur He37% | → $9 | Initiates | → Buy | Get Alert |
| 09/27/2022 | Buy Now | 2122.22% | SVB Leerink | Daina Graybosch42% | $25 → $28 | Maintains | Outperform | Get Alert |
| 09/15/2022 | Buy Now | 376.19% | JMP Securities | Reni Benjamin45% | → $6 | Initiates | → Market Outperform | Get Alert |
| 05/18/2022 | Buy Now | 1884.13% | SVB Leerink | Daina Graybosch42% | $23 → $25 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for LAVA Therapeutics (LVTX) stock?
The latest price target for LAVA Therapeutics (NASDAQ:LVTX) was reported by HC Wainwright & Co. on February 27, 2025. The analyst firm set a price target for $1.50 expecting LVTX to rise to within 12 months (a possible 19.05% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for LAVA Therapeutics (LVTX)?
The latest analyst rating for LAVA Therapeutics (NASDAQ:LVTX) was provided by HC Wainwright & Co., and LAVA Therapeutics downgraded their neutral rating.
When was the last upgrade for LAVA Therapeutics (LVTX)?
There is no last upgrade for LAVA Therapeutics
When was the last downgrade for LAVA Therapeutics (LVTX)?
The last downgrade for LAVA Therapeutics NV happened on February 27, 2025 when HC Wainwright & Co. changed their price target from $2 to $1.5 for LAVA Therapeutics NV.
When is the next analyst rating going to be posted or updated for LAVA Therapeutics (LVTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LAVA Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LAVA Therapeutics was filed on February 27, 2025 so you should expect the next rating to be made available sometime around February 27, 2026.
Is the Analyst Rating LAVA Therapeutics (LVTX) correct?
While ratings are subjective and will change, the latest LAVA Therapeutics (LVTX) rating was a downgraded with a price target of $2.00 to $1.50. The current price LAVA Therapeutics (LVTX) is trading at is $1.26, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.